Longitudinal study findings support a relationship between body mass index and the timing of puberty in boys, with a link found between obesity and precocious gonadarche.
Collagenopathies could account for around one in 10 cases of familial short stature even when there are no obvious signs of dysplasia, say researchers.
A 6 years and 5-month-old girl with Prader-Willi Syndrome (PWS) attends endocrine clinic with her mother. She was first seen by the endocrine team at 18 months old and the referral was made by a geneticist. Mum reports she has been obsessive and extremely challenging with her behaviour around food, and she is concerned about her child’s weight.
A study of children with Noonan syndrome treated in clinical practice shows a good response to growth hormone treatment, with the majority achieving a height within population norms.
A systematic review and meta-analysis suggests that girls with idiopathic central precious puberty who are treated with gonadotropin-releasing hormone analogue therapy may expect to have a higher final adult height and lower BMI than if they do not receive the treatment.
A single measurement of plasma levels of a fragment of type X collagen may give an instant picture of how fast a child is growing, say researchers.
Rare copy number variants have been identified in a study of children who have growth hormone insensitivity or insulin-like growth factor-1 insensitivity, shedding light on the genetic basis of their conditions.
The C-type natriuretic peptide analogue vosoritide significantly increases the growth rate of children with achondroplasia, indicate the results of a randomised, double-blind phase 3 study published in The Lancet.
Following the publication of the long-term mortality findings of the SAGhE consortium, we discuss the safety profile of growth hormone with consortium member Stefano Cianfarani.